AR034771A1 - Formulacion vacunal potenciada por la combinacion de un adn con un antigeno - Google Patents

Formulacion vacunal potenciada por la combinacion de un adn con un antigeno

Info

Publication number
AR034771A1
AR034771A1 ARP020102614A AR034771A1 AR 034771 A1 AR034771 A1 AR 034771A1 AR P020102614 A ARP020102614 A AR P020102614A AR 034771 A1 AR034771 A1 AR 034771A1
Authority
AR
Argentina
Prior art keywords
antigen
components
potentiated
dna
combination
Prior art date
Application number
Other languages
English (en)
Inventor
Cabrera Santiago Duenas
Grillo Juan Morales
Lajonchere Ponce De Leon Liz Alvarez
Lasa Alexis Musacchio
Feyt Rolando Pajon
Rodriguez Ariel Vina
Obregon Julio C Alvarez
Rivero Nelson Acosta
Donato Gillian Martinez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR034771A1 publication Critical patent/AR034771A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formulación de antígenos vacunales, la cual contiene como componentes principales: a) uno o varios ADN que expresan una o varias proteínas en el individuo inmunizado y b) un antígeno viral en proporciones adecuadas. Un efecto potenciador ejerce al menos uno de los componentes sobre la respuesta inmune generada contra el otro. Nuevas formulaciones, minimizando el número de componentes que sean capaces de ampliar y potenciar el espectro de respuesta inmune contra diferentes entidades patogénicas (Virus Hepatitis B y Virus Hepatitis C) y de generar vacunas combinadas contra entidades patógenas. Estas formulaciones pueden ser aplicadas en la industria farmacéutica para uso profiláctico y/o terapéutico en humanos.
ARP020102614 2001-07-16 2002-07-12 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno AR034771A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20010171A CU23244A1 (es) 2001-07-16 2001-07-16 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno

Publications (1)

Publication Number Publication Date
AR034771A1 true AR034771A1 (es) 2004-03-17

Family

ID=40091632

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102614 AR034771A1 (es) 2001-07-16 2002-07-12 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno

Country Status (16)

Country Link
US (2) US20040234543A1 (es)
EP (1) EP1417973B1 (es)
JP (1) JP4217611B2 (es)
KR (1) KR100905249B1 (es)
CN (1) CN1241644C (es)
AR (1) AR034771A1 (es)
AU (1) AU2002325783B2 (es)
BR (1) BR0211181A (es)
CA (1) CA2453260C (es)
CU (1) CU23244A1 (es)
ES (1) ES2393546T3 (es)
MX (1) MXPA04000431A (es)
MY (1) MY134885A (es)
RU (1) RU2294212C2 (es)
WO (1) WO2003007986A2 (es)
ZA (1) ZA200400286B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
WO2006078979A2 (en) 2005-01-20 2006-07-27 Nature Technology Corp. Vectors and methods for genetic immunization
EP3246409A1 (en) 2007-05-29 2017-11-22 Nature Technology Corporation Antibiotic-resistance-free vectors
CN104830789A (zh) * 2015-05-05 2015-08-12 杨光华 基于hcv1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2032381C (en) * 1989-12-18 2006-02-21 Peter E. Highfield Viral agent
CA2044296A1 (en) * 1990-06-12 1991-12-13 Hiroaki Okamoto Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US6689757B1 (en) * 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
CN1044092C (zh) 1997-02-26 1999-07-14 上海医科大学 抗原－抗体－重组dna复合型疫苗
FR2760367B1 (fr) * 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
WO1998050556A2 (en) * 1997-05-06 1998-11-12 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
DE19915178A1 (de) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies

Also Published As

Publication number Publication date
RU2004104357A (ru) 2005-07-10
MXPA04000431A (es) 2004-03-18
WO2003007986A3 (es) 2004-03-04
CA2453260C (en) 2013-03-19
WO2003007986A2 (es) 2003-01-30
EP1417973B1 (en) 2012-08-29
KR100905249B1 (ko) 2009-06-29
WO2003007986A8 (es) 2004-04-29
BR0211181A (pt) 2004-08-10
RU2294212C2 (ru) 2007-02-27
US20100316669A1 (en) 2010-12-16
ZA200400286B (en) 2004-10-04
ES2393546T3 (es) 2012-12-26
US20040234543A1 (en) 2004-11-25
JP4217611B2 (ja) 2009-02-04
EP1417973A2 (en) 2004-05-12
JP2004537552A (ja) 2004-12-16
MY134885A (en) 2007-12-31
CN1529616A (zh) 2004-09-15
AU2002325783B2 (en) 2006-08-17
CU23244A1 (es) 2007-10-17
US8691234B2 (en) 2014-04-08
CA2453260A1 (en) 2003-01-30
CN1241644C (zh) 2006-02-15
KR20040028924A (ko) 2004-04-03

Similar Documents

Publication Publication Date Title
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
BR112022014830A2 (pt) Formulações de vacina para coronavírus
CY1113078T1 (el) Συνθεση πολυσθενους εμβολιου
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
EP1326633A4 (en) COMPOSITION WITH IMMUNOGENIC MICROPARTICLES
HUP0101047A1 (hu) Kombinált vakcinakészítmények
DE60024112D1 (de) Influenzavirus-impfstoffzusammensetzung
AR032597A1 (es) Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
CY1110290T1 (el) Εμβολιο χοιρειου κυκλοϊου και κοκκοϊου
WO2022140364A3 (en) African swine fever (asf) virus vaccines
PH12018502403A1 (en) Hiv vaccine formulation
BR112023019301A2 (pt) Formulações de vacina de coronavírus
AR021414A1 (es) Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal
ZA202400113B (en) Adjuvanted inactivated recombinant rabies virus vectored coronavirus vaccine formulations
AR034771A1 (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
WO2005012538A3 (en) Accelerated vaccination
CU23496A1 (es) Composición vacunal contra el virus de la hepatitis c
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
WO2002036160A3 (es) Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica
UY31574A1 (es) Vacunas contra la malaria

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee